Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients allowing women to live longer or remain disease-free for longer if the medicines are given before and after surgery as well as in advanced stages of disease.

    Key data being presented include:

    - Herceptin before surgery: Results from the NOAH (NeOAdjuvant Herceptin)
      phase III study showed that women with locally advanced HER2-positive
      breast cancer who started a combination of Herceptin and standard
      chemotherapy prior to surgery had a significantly greater chance of
      living free of their disease (event-free survival) three years after
      initiation of treatment as compared to women who were receiving pre-
      operative chemotherapy alone.

    - Xeloda in early breast cancer: Early data from an independent study in
      Finland and Sweden indicate that the chemotherapy pill Xeloda, which is
      already proven in advanced breast cancer, may also reduce the
      recurrence of early breast cancer and help women live longer. This is
      one of 20 Xeloda abstracts that have been accepted for presentation
      during SABCS.

    - Avastin in advanced breast cancer: First efficacy results from the
      largest ever safety study of Avastin in a real-life setting, which
      involved more than 2,000 patients with locally recurrent or metastatic
      breast cancer, confirm that Avastin can be used with a broad range of
      chemotherapy treatments giving patients a median of almost 10 months
      without their disease getting worse. The results, which are one of 24
      separate Avastin data presentations during SABCS, confirm that Avastin
      based therapy is essential for improving the li
'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Established and new medical technology service ... penetrate the growing Eastern European medical devices market. ... team and regional/local offices, reducing the costs incurred ... crucial advantage as medical technology service providers are ... New analysis from Frost & Sullivan, Medical Technologies ...
(Date:9/30/2014)... , Sept. 30, 2014 CytRx ... research and development company specializing in oncology, today ... clinical trial evaluating aldoxorubicin compared to topotecan in ... who have relapsed or were refractory to prior ... widely-used chemotherapeutic agent, doxorubicin. CytRx has received Orphan ...
(Date:9/29/2014)...  Repeated exposure to broad-spectrum antibiotics in the first ... obesity, say researchers from The Children,s Hospital of ... on data from electronic health records from the extensive ... that children with four or more exposures to broad ... be at risk for obesity. The study, published online ...
Breaking Medicine Technology:Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 2Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... reach USD 8,020.1 million by 2020, according to ... Growing demand for personalized medicine and theranostics, and ... are expected to be key factors driving market ... growing global base of geriatric population and chronic ...
(Date:9/30/2014)... During this online virtual event, ... health including achieving hormonal balance, relieving menopause symptoms, ... , The details of the ... 6-9, 2014, Location: Online Event, Registration: Complimentary , ... , Monday, October 6th, Steven F. Hotze, M.D., ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... Washington, DC (PRWEB) September ... **MEDIA ADVISORY** , ... Contact:    Anne Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Give Hope® Celebration , ... , Address:    The Army and ...
(Date:9/30/2014)... York (PRWEB) September 30, 2014 ... of Hudson Allergy , will discuss how restaurants ... allergies and other special dietary restrictions at the ... & Food Service Professionals, October 21 in New York ... this incredibly important topic to such an engaged industry ...
Breaking Medicine News(10 mins):Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... how we put the brakes on a racing heartbeat. ... Chicago explain in the May 11 issue of Circulation Research ... the rapid beating of the heart's "fight-or-flight" reaction to adrenaline. ... is responsible for setting the pace of the beating heart, ...
... The central government is aiming for 100 percent registration of ... Death Act 1969 that would simplify the process, an ... serious issue as this helps in maintaining a record for ... the birth registration record is 64 percent as some of ...
... 100 percent registration of births by 2010 by amending the ... simplify the process, an official said Friday. ,'Registration ... maintaining a record for a person for his or her ... percent as some of the states have still not implemented ...
... a single sphere in the US they would like to ... is the cooked chickens market. ,The U.S. ... to familiarize the U.S. market with its cooked chickens." ... about such common practices among Chinese farmers, like flooding crops ...
... of motor disorders: stiffness, slowness, tremors, difficulties walking and ... other symptoms with narcolepsy, a sleep disorder characterized by ... and general sleep disorder. ,Now a team ... why the two disorders share something in common: ...
... receiver Robert Sillen, hired to improve healthcare for state ... his jurisdiction. ,According to Sillen the 50-page ... and protect California communities from diseases carried by inmates ... says, taxpayers will get more for their dollar from ...
Cached Medicine News:Health News:Slowing the Racing Heart 2Health News:Government to Amend Birth Registration Act 2Health News:Government to Amend Birth Registration Act 2Health News:China Eyeing US Cooked Chickens Market 2Health News:UCLA Researchers Discover Link Between Parkinsons and Narcolepsy 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: